Skip to content

Study · Animal study (in vivo) · mouse · 2003

8 results

Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.

Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ

Journal of immunology (Baltimore, Md. : 1950)1 Jan 2003Cited by 60 (Europe PMC)

PMID12496414 (opens in a new tab)DOI10.4049/jimmunol.170.1.308 (opens in a new tab)PepBankPUB-12496414
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In wild-type and VPAC2-null mice, but not in transgenic mice, exogenous VIP increased the number of IL-4-secreting CD4 T cells after TCR stimulation.

    In plain wordsIn mice, VIP raised the number of IL-4-producing T cells in normal and receptor-null mice but not in transgenic mice.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseIL-4-secreting CD4 T cells after exogenous VIP
    Study

    mousen: not reported in source

    in vitro and in vivo, wild-type and VPAC2-null mice
    Comparator
    No VIP
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Flexible responsiveness of CD4 T cells from N and K mice, but not T mice, to exogenous VIP in vitro and in vivo is shown by increased numbers of IL-4-secreting CD4 T cells
  2. 02AnimalAnimal study (in vivo)Mechanism

    In wild-type and VPAC2-null mice, but not in transgenic mice, exogenous VIP increased IL-4 secretion after TCR stimulation.

    In plain wordsIn mice, VIP raised IL-4 release from T cells in normal and receptor-null mice but not in transgenic mice.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseIL-4 secretion after exogenous VIP
    Study

    mousen: not reported in source

    in vitro and in vivo, wild-type and VPAC2-null mice
    Comparator
    No VIP
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Flexible responsiveness of CD4 T cells from N and K mice, but not T mice, to exogenous VIP in vitro and in vivo is shown by increased numbers of IL-4-secreting CD4 T cells, greater secretion of IL-4 and IL-10
  3. 03AnimalAnimal study (in vivo)Mechanism

    In wild-type and VPAC2-null mice, but not in transgenic mice, exogenous VIP increased IL-10 secretion after TCR stimulation.

    In plain wordsIn mice, VIP raised IL-10 release from T cells in normal and receptor-null mice but not in transgenic mice.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseIL-10 secretion after exogenous VIP
    Study

    mousen: not reported in source

    in vitro and in vivo, wild-type and VPAC2-null mice
    Comparator
    No VIP
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Flexible responsiveness of CD4 T cells from N and K mice, but not T mice, to exogenous VIP in vitro and in vivo is shown by increased numbers of IL-4-secreting CD4 T cells, greater secretion of IL-4 and IL-10
  4. 04AnimalAnimal study (in vivo)Mechanism

    In wild-type and VPAC2-null mice, but not in transgenic mice, exogenous VIP decreased IFN-gamma secretion after TCR stimulation.

    In plain wordsIn mice, VIP lowered IFN-gamma release from T cells in normal and receptor-null mice but not in transgenic mice.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseIFN-gamma secretion after exogenous VIP
    Study

    mousen: not reported in source

    in vitro and in vivo, wild-type and VPAC2-null mice
    Comparator
    No VIP
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Flexible responsiveness of CD4 T cells from N and K mice, but not T mice, to exogenous VIP in vitro and in vivo is shown by increased numbers of IL-4-secreting CD4 T cells, greater secretion of IL-4 and IL-10, and lesser secretion of IFN-gamma after TCR stimulation with VIP.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In T cell cultures from VPAC2-transgenic mice, removing VIP with VIPase IgG normalized the raised number of IL-4-secreting CD4 T cells.

    In plain wordsIn mouse T cells grown in the lab, removing VIP lowered the raised number of IL-4-producing T cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseIL-4-secreting CD4 T cells after VIP removal
    Study

    mousen: not reported in source

    TCR-stimulated T cell cultures from transgenic mice
    Comparator
    Untreated cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    eliminating VIP from TCR-stimulated T cell cultures with VIPase IgG normalizes the elevated number of IL-4-secreting CD4 T cells

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In T cell cultures from VPAC2-transgenic mice, removing VIP with VIPase IgG decreased IL-4 secretion.

    In plain wordsIn mouse T cells grown in the lab, removing VIP lowered IL-4 release.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseIL-4 secretion after VIP removal
    Study

    mousen: not reported in source

    TCR-stimulated T cell cultures from transgenic mice
    Comparator
    Untreated cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    eliminating VIP from TCR-stimulated T cell cultures with VIPase IgG normalizes the elevated number of IL-4-secreting CD4 T cells, decreases the secretion of IL-4 and IL-10

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 07LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In T cell cultures from VPAC2-transgenic mice, removing VIP with VIPase IgG decreased IL-10 secretion.

    In plain wordsIn mouse T cells grown in the lab, removing VIP lowered IL-10 release.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseIL-10 secretion after VIP removal
    Study

    mousen: not reported in source

    TCR-stimulated T cell cultures from transgenic mice
    Comparator
    Untreated cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    eliminating VIP from TCR-stimulated T cell cultures with VIPase IgG normalizes the elevated number of IL-4-secreting CD4 T cells, decreases the secretion of IL-4 and IL-10

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 08LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In T cell cultures from VPAC2-transgenic mice, removing VIP with VIPase IgG increased IFN-gamma secretion.

    In plain wordsIn mouse T cells grown in the lab, removing VIP raised IFN-gamma release.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseIFN-gamma secretion after VIP removal
    Study

    mousen: not reported in source

    TCR-stimulated T cell cultures from transgenic mice
    Comparator
    Untreated cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    eliminating VIP from TCR-stimulated T cell cultures with VIPase IgG normalizes the elevated number of IL-4-secreting CD4 T cells, decreases the secretion of IL-4 and IL-10, and increases the secretion of IFN-gamma.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.